86 results
8-K
EX-10.1
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
capital.
(l) Litigation. Except as set forth on Schedule 3.1(l), there is no action, suit, inquiry, notice of violation, proceeding or investigation … ) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC
8-K
EX-10.2
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
and expenses incurred in defending any litigation, proceeding or other action or claim. Notwithstanding the provisions hereof, a Placement Agent’s share
8-K
EX-99.1
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology
8-K
rw2evmhz63yg0p
30 Apr 24
Regulation FD Disclosure
8:17am
8-K
qgpgyy
18 Apr 24
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
9:46pm
8-K
EX-99.1
a1fo7feakez dhwmf
18 Apr 24
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
9:46pm
8-K/A
EX-99.1
tzisuyoyz79ntaw3r
2 Apr 24
Departure of Directors or Certain Officers
5:12pm